Semaglutide and the Risk of Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.37275/oaijmr.v6i2.884Keywords:
Glucagon-like peptide-1 receptor agonist, Meta-analysis, NAION, Non-arteritic anterior ischaemic optic neuropathy, SemaglutideAbstract
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as an effective treatment for type 2 diabetes mellitus and obesity management. However, recent pharmacovigilance and observational studies have raised concerns regarding a potential association between semaglutide use and non-arteritic anterior ischaemic optic neuropathy (NAION), a serious form of optic neuropathy causing sudden vision loss. We conducted a systematic review and meta-analysis of observational studies examining the association between semaglutide exposure and NAION risk. We searched PubMed, Embase, and Google Scholar without date restrictions, with the final search completed on 31 March 2026. Study selection was based on predefined inclusion criteria, and quality was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects model was used to estimate pooled hazard ratios (HR) with 95% confidence intervals (CI). Heterogeneity was quantified using the I² statistic. Publication bias was examined using funnel plots and Egger’s regression test. Six observational studies comprising 699,141 participants were included in the meta-analysis. Overall, semaglutide was associated with a significantly increased risk of NAION (pooled HR 1.802; 95% CI 1.221–2.658; p = 0.003). Substantial heterogeneity was observed (I² = 72.8%, Q = 18.37, p = 0.003). Subgroup analyses revealed that the positive association was driven by four prospective cohort studies reporting elevated NAION risk (HR = 2.402; 95% CI 1.662–3.468), whereas two retrospective studies reported null associations (HR = 0.98; 95% CI 0.60–1.60). Sensitivity analyses demonstrated robustness of the primary finding. In conclusion, this meta-analysis provides evidence of a potential increased risk of NAION associated with semaglutide use in observational studies, particularly among individuals with type 2 diabetes and obesity. Clinical awareness of this signal is warranted, and further prospective investigation is recommended.
Downloads
Published
Issue
Section
License
Authors retain copyright in their articles and grant Open Access Indonesian Journal of Medical Reviews (OAIJMR) the non-exclusive right of first publication. Unless otherwise stated on an individual article, published work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). Users may share and adapt the work for non-commercial purposes provided that appropriate attribution is given, changes are indicated, and adaptations are distributed under the same license. Copyright in the journal website, logo, layout, and other publisher-owned materials is separate from copyright in individual articles.
How to Cite
Article Metrics
Views and downloads recorded by this journal. Citation count from OpenAlex.